Polymorphisms of folate metabolism genes in patients with cirrhosis and hepatocellular carcinoma

Table 6 Regression analysis of data from multiple logistic analyzed clinical parameters and polymorphisms in patients with hepatocellular carcinoma tumors divided into stages 0 and tumore in stages A and B, C and D according barcelona clinic liver cancer criteria

Variables	Stage 0 e A	Estage B, C e D	OR (95%CI)1	P
	Pacientes n (%)	Pacientes n (%)
Alpha fetoprotein
> 500 ng/mL	22 (84.6)	21 (46.7)	Reference	Reference
< 500 ng/mL	4 (15.4)	24 (53.3)	2.66 (0.55-12.72)	0.22
Hepatitis B virus
Absence	25 (96.2)	38 (84.4)	Reference	Reference
Presence	1 (3.85)	7 (15.6)	4.06 (0.34-48.29)	0.27
Hepatitis C virus
Absence	12 (46.2)	22 (48.9)	Reference	Reference
Presence	14 (53.8)	23 (41.1)	1.43 (0.35-5.78)	0.61
Steatohepatitis
Absence	26 (100)	42 (93.3)	Reference	Reference
Presence	00 (00)	3 (6.7)	3	0.99
Diabetes
Absence	18 (69.2)	32 (71.1)	Reference	Reference
Presence	8 (30.8)	13 (28.9)	0.25 (0.03-1.63)	0.15
Death
No	24 (92.3)	17 (37.8)	Reference	Reference
Yes	2 (7.7)	28 (62.2)	25.3 (3.67-174.38)	0.0012
MTHFR A1298C
AA	10 (38.5)	22 (48.9)	Reference	Reference
AC/CC	16 (61.5)	23 (51.1)	0.93 (0.22-3.86)	0.92
MTHFR C677T
CC	11 (42.3)	17 (37.8)	Reference	Reference
CT/TT	15 (57.7)	28 (62.2)	1.65 (0.34-7.97)	0.53
MTR A2756G
AA	18 (69.2)	28 (62.2)	Reference	Reference
AG/GG	8 (30.8)	17 (37.8)	0.78 (0.18-3.43)	0.75
MTRRA66G
AA	4 (15.4)	8 (17.8)	Reference	Reference
AG/GG	22 (84.6)	37 (82.2)	1.09 (0.16-7.30)	0.93

¹OR: Odds ratio, CI: Confidence interval;

²Statistically significant at P ≤ 0.05;

³Could not calculate due to numerical proximity.